4
Changes in Ownership
Aurinia Pharmaceuticals Inc. Filed Acc 0001628280-21-019051
EVP of Research sold 32,500 shares at an average $23.99 ($779,533)
- EVP of Research acquired 27,136 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Huizinga Robert Bindert · EVP of Research
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-09-21 | Exercise or conversion : show line 1 in the form | +16,000 | $2.63 | $42,080 | 122,092 | D |
| 2021-09-21 | Exercise or conversion : show line 2 in the form | +11,136 | $3.20 | $35,635 | 133,228 | D |
| 2021-09-21 | Sale : show line 3 in the form | −27,136 | $24.05 | $652,621 | 106,092 | D |
| 2021-09-21 | Sale : show line 4 in the form | −5,364 | $23.66 | $126,912 | 100,728 | D |
| Open-market sales · 32,500 sh · avg $23.99 · $779,533 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2021-09-21 | Exercise or conversion : show line 5 in the form Stock Option (right to buy) | −16,000 | 0 | D |
| 2021-09-21 | Exercise or conversion : show line 6 in the form Stock Option (right to buy) | −11,136 | 98,864 | D |
Loading xslF345X03/wf-form4_163234399960979.xml…